Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities

Few terms in biopharma are used as loosely as "platform," and the differences between a product, technology, and manufacturing platform matter once a program reaches development.

Mathias Kahl, Head of Development at IDT Biologika, examines how prior knowledge can be applied across modalities, from monoclonal antibodies to viral vectors, without forcing every candidate into the same process. The paper considers where platforms transfer and where they do not, how materials and supply planning fit in, and how analytical and regulatory strategy can draw on earlier programs. It also looks at why the experience behind a platform may count for more than the equipment itself.

Explore the analysis to see how standardization and customization can work together.